Antiretroviral effect of combined zidovudine and reduced glutathione therapy in murine AIDS

AIDS Res Hum Retroviruses. 1997 Sep 1;13(13):1093-9. doi: 10.1089/aid.1997.13.1093.


A combination of antiretroviral drugs acting at different points in the virus replication cycle was evaluated in a murine retrovirus-induced immunodeficiency model of AIDS (MAIDS). Intramuscular administration of high doses of reduced glutathione (GSH, 100 mg/mouse/day) and AZT (0.25 mg/ml in drinking water) was found to reduce lymphoadenopathy (92%), splenomegaly (80%), and hypergammaglobulinemia (90%) significantly more than AZT alone. Combined treatment resulted in a reduction in proviral DNA content of 69, 66, and 60%, respectively, in lymph nodes, spleen, and bone marrow. Furthermore, the stimulation index of B cells was also significantly higher in animals receiving GSH and AZT whereas additional responses were not observed in the T cell stimulation index and blood lymphocyte phenotype analyses. In conclusion, the administration of high doses of GSH and AZT, a new combination of antiviral drugs, seems to provide additional advantages compared to single-agent therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antiviral Agents / therapeutic use*
  • DNA, Viral / isolation & purification
  • Disease Progression
  • Drug Therapy, Combination
  • Female
  • Glutathione / therapeutic use*
  • Hematologic Tests
  • Lymph Nodes / pathology
  • Lymphocyte Activation
  • Mice
  • Mice, Inbred C57BL
  • Murine Acquired Immunodeficiency Syndrome / drug therapy*
  • Murine Acquired Immunodeficiency Syndrome / pathology
  • Proviruses / genetics
  • Zidovudine / therapeutic use*


  • Antiviral Agents
  • DNA, Viral
  • Zidovudine
  • Glutathione